The present study demonstrated a weak but significant association between high plasma sPD-L1 levels and shorter OS in NSCLC patients treated with anti-PD-1/anti-PD-L1 therapies in a two-year follow-up. The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.